Since m2gen is fully funded :-)) I have set up camp here and will buy from time to time on dips, if it actually does dip. Because m2gen is alive, dnaprint will rock! That is my opinion.
DNAPrint also has two other pharmacogenomic products under development. It is working with the H. Lee Moffitt Cancer Center on the development of OVANOME(TM), a test for predicting an ovarian cancer patient's response to TAXOL/Carboplatin treatment, and STATINOME(TM), a test for predicting adverse response to cholesterol lowering medicines known as Statins. "Our DNA technology is advancing into new areas while we continue to develop our core genealogy business," Dr. Frudakis said. http://www.advfn.com/news_dnaprint-genomics-chairman-hector-gomez-tells-annual-meeting-that-company-...